Crinetics director sells 3,000 shares at $40

Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares of Common Stock in an open-market transaction at $40.00 per share.

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares of Common Stock in an open-market transaction at $40.00 per share. The trade occurred on July 2, 2026 and was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. Following this sale, he directly holds 19,225 Crinetics shares.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 1 txn

Insider Vivaldi Coelho Rogerio

Role Director

Sold 3,000 shs ($120K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$40.00	$120K

Holdings After Transaction: Common Stock — 19,225 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.
2. F2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share.

Key Figures

Shares sold: 3,000 shares Sale price: $40.00 per share Shares held after sale: 19,225 shares +1 more

4 metrics

Shares sold 3,000 shares Open-market sale on July 2, 2026

Sale price $40.00 per share Price for Common Stock sold

Shares held after sale 19,225 shares Director’s direct holdings following transaction

Net shares sold 3,000 shares Net-sell direction per transaction summary

Key Terms

Rule 10b5-1 trading plan, open market transactions, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market transactions financial

"The common stock was sold by the Reporting Person in open market transactions on the transaction date"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

Common Stock financial

"The common stock was sold by the Reporting Person in open market transactions"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The sale reported in this Form 4 was effected automatically"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Crinetics (CRNX) director Vivaldi Coelho Rogerio report?

Director Vivaldi Coelho Rogerio reported selling 3,000 shares of Crinetics Common Stock. The shares were sold in an open-market transaction at $40.00 per share, and the transaction was disclosed on a Form 4 insider filing.

At what price did the Crinetics (CRNX) director sell his shares?

The director sold his Crinetics shares at $40.00 per share. This price applied to the 3,000 Common Stock shares sold in open-market transactions on the reported transaction date, according to the Form 4 footnotes.

How many Crinetics (CRNX) shares does the director hold after the sale?

After the sale, the director directly holds 19,225 Crinetics shares. This post-transaction holding reflects his remaining Common Stock position as reported in the Form 4 filing following the 3,000-share open-market sale.

Was the Crinetics (CRNX) insider sale made under a Rule 10b5-1 trading plan?

Yes, the sale was executed under a Rule 10b5-1 trading plan. The plan was adopted by the reporting person on December 11, 2025, and the transaction was carried out automatically pursuant to that pre-arranged plan.

What type of security did the Crinetics (CRNX) director sell in this Form 4?

The director sold shares of Crinetics Common Stock. The Form 4 specifies that 3,000 non-derivative Common Stock shares were sold in open-market transactions at a sale price of $40.00 per share.

Does the Crinetics (CRNX) Form 4 indicate an open-market sale or a private transaction?

The Form 4 describes the transaction as an open-market sale of Common Stock. Footnotes clarify that the common stock was sold by the reporting person in open market transactions at a sale price of $40.00 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vivaldi Coelho Rogerio

(Last) (First) (Middle)

C/O CRINETICS PHARMACEUTICALS, INC.

6055 LUSK BOULEVARD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		S(1)		3,000	D	$40(2)	19,225	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

2. The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $40.00 per share.

Remarks:

	/s/ Tobin Schilke, as attorney-in-fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)